Orphan Drug Designation (ODD) has long been one of the earliest and most telling signals in a rare disease program. Sponsors pursue ODD when they have a foundation of data, whether nonclinical or early clinical, that supports medical plausibility. This designation reflects confidence in both the science and the development strategy, often secured at the transition from concept to execution. Over the past several years, ODD activity has remained consistently strong, even as the broader environment has become more focused and selective, with a higher bar for data, strategy, and execution. At the same time, orphan drug approvals continue to reinforce the central role rare disease programs play in the innovation landscape. Taken together, these trends reflect sustained advancement across rare disease programs and reinforce the importance of orphan designation as a foundational step in successful development strategies.
A company cannot secure an ODD without supporting data. This evidence is often nonclinical or early clinical, including single-patient or biomarker-driven outcomes, and thus, ODD signals that a program has cleared an important scientific hurdle. When obtained at the preclinical stage, it often reflects momentum toward a pre-IND meeting, followed by IND submission and initiation of clinical studies. When obtained clinically, it signals that meaningful human proof-of-concept is in hand.
An ODD provides strategic advantages across drug development pipelines, including seven years of U.S. market exclusivity upon approval, potential tax credits for qualified clinical testing, and waiver of certain FDA fees. And in the US, ODD designations granted by the FDA's Office of Orphan Products Development have held steady in the current environment and may even have strengthened.
Orphan Drug Designations Granted Over the Last 5 Years (2021–2025)
| Year | Orphan Drug Designations Granted |
|---|---|
| 2021 | 364 |
| 2022 | 402 |
| 2023 | 376 |
| 2024 | 481 (a record high) |
| 2025 | 400 |
As of March 31, the FDA has granted 142 ODDs in 2026 (as of April 23), and at that pace, the year is on track to match or exceed 2024's record.
This reflects a continued focus on execution, with companies advancing programs despite tighter capital and evolving regulatory expectations, and it underscores the sustained commitment driving rare disease drug development.
Orphan Drug Approval Landscape
The approvals landscape is equally compelling, with Q1 2026 already demonstrating strong momentum. More than half of all novel drugs approved by the FDA over the past five years have been for rare diseases.
CDER figures capture new molecular entities and novel biologics under NDA/BLA. CBER figures capture novel BLAs, including cell and gene therapies.
| Year | CDER Total Novel Approvals | CDER Orphan Approvals (% of Total) | CBER Total Novel BLAs | CBER Orphan Approvals (% of Total) |
|---|---|---|---|---|
| 2021 | 50 | 26 (52%) | 10 | 5 (50%) |
| 2022 | 37 | 20 (54%) | 8 | 5 (63%) |
| 2023 | 55 | 28 (51%) | 18 | 12 (67%) |
| 2024 | 50 | 26 (52%) | 12 | 7 (58%) |
| 2025 | 50 | 26 (52%) | 12 | 5 (42%) |
2026 Emerging Signals
CDER: Approvals in Q1 2026 have reinforced the Center's ongoing commitment to rare disease. Zycubo (Menkes disease) achieved traditional approval, while Yuviwel (achondroplasia) and Avlayah (Hunter syndrome/MPS II) were both approved under the Accelerated Approval pathway; Avlayah on the basis of Phase 1/2 data demonstrating a meaningful reduction in disease-relevant biomarkers. All three programs were supported by a combination of expedited and rare disease designations, including Orphan Drug, Priority Review, Fast Track, and Rare Pediatric Disease (RPD), and each received an RPD Priority Review Voucher.
CBER: 2026 has already produced two landmark gene therapy approvals. Kresladi (marnetegragene autotemcel), approved March 26, is the first gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), supported by Orphan Drug, RPD, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations. Otarmeni (lunsotogene parvec-cwha), approved April 23, is the first-ever gene therapy for genetic hearing loss and the first treatment in history to restore a neurosensory function to normal levels. Carrying a full designation stack: Orphan Drug, RPD, Fast Track, and RMAT, Otarmeni is also the first approval made under the Commissioner's National Priority Voucher program, with FDA completing review in approximately 60 days. Regeneron announced that the therapy will be offered free of charge to patients in the US.
Together, these approvals reflect strong pipeline momentum, with additional BLA and NDA decisions for rare disease programs expected in the near term.
A consistent theme across all of these programs is the coordinated layering of multiple regulatory tools, Orphan Drug, Rare Pediatric Disease, RMAT, Breakthrough Therapy, Fast Track, and Priority Review, to accelerate both development and review timelines. Newer FDA initiatives such as the RDEP, RDEA, and START, which offer greater flexibility, earlier alignment, and a streamlined path toward approval, will almost certainly play a role.
If you have questions about how orphan designation and related regulatory tools may fit into your program strategy, please get in touch: contactus@raremoonconsulting.com.